Clinical Trials · NCT03789578
A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 30
- Start date
- Jan 2019
- Locations
- 1 site, Germany
- Primary endpoint
- AUCI287, 0-tz, area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation after a single dose